

## Q4FY20 Result Update ICICI Bank Limited

### Mixed quarter; elevated slippages a concern

ICICI Bank reported a mixed Q4FY20 with negatives marginally outweighing the positives. Higher than expected novel coronavirus related provisioning led to profit after tax (PAT) coming in below consensus and our estimates and increased the provision coverage ratio (PCR) to 75.7% as against 70.6% in Q4FY19. Advances growth of 10% YoY was also below our estimate. Slippages rose 22% QoQ to INR 5,300 crore led by corporates, whereas that of retail and small and medium enterprises (SME) fell 32% QoQ. Overall management commentary was cautious. The bank will focus on attracting granular deposits. The management refrained from offering any guidance for FY21 in wake of economic uncertainties due to the pandemic. The few positives were: healthy term deposit growth, highest ever net interest margin (NIM) and in-line core operating profitability. Since it is too early to ascertain the impact of COVID-19, our estimates for FY21E will be pushed forward by at least a year due to: a) Moderation in loan growth; and b) Accelerated slippages due to COVID-19. Though we have cut our FY21 earnings estimates, we believe the bank is best placed to weather this storm given its strong current account-saving account (CASA) ratio, high PCR and a significant proportion of retail advances in its loan mix. We maintain our BUY recommendation.

#### Margin expansion, healthy non-interest income led to strong growth in core operating performance

Net interest income (NII) grew 17.1% YoY to INR 8,900 crore led by a 10% growth in advances and 15bps expansion in net interest margin (NIM). Non-interest income grew 17.5% to INR 4,250 crore led by 55/26% growth in treasury/dividend income, respectively. Net revenue/operating expenditure (OPEX) grew 17.3/15.7%, respectively, leading to 18.6% YoY growth in pre-operating profit (PPOP) at INR 7,400 crore.

#### Slippages remain elevated; higher write-offs led to improvement in asset quality

Slippages stood at INR 5,300 crore (up 22% QoQ), higher than consensus estimates. Of this, that from corporates and retail & SME stood at INR 4,000 crore (up 62% QoQ) and INR 1,300 crore (down 32% QoQ), respectively. Elevated corporate slippages was largely due to 2 overseas accounts: 1) An oil & gas; and 2) A healthcare group. Both were classified as non-performing assets (NPAs) in Q4. However, higher write-off (INR 5,500 crore versus INR 2,500 crore QoQ) restricted GNPA/NNPA to 6.04/1.54%, a QoQ improvement of 35/6bps, respectively. Overall corporate and SME loan book with a rating of BB & below tapered by 4% QoQ and now stands at INR 16,700 crore.

#### Growth in advances led by retail and SME; deposits growth led by term deposits

Loans and advances grew 10% YoY to INR 6,453 billion, driven by retail and SME book. Retail book grew 16% to INR 4,080 billion, constituting 63% of overall loan book. Loans to MSMEs grew 25% to INR 229 billion. However, corporate loan book grew 5% INR 1,605 billion. The bank's plan is to reduce its overseas book, with the latter now de-growing for 16 quarters in a row. Even in Q4FY20, this book de-grew 14% and now constitutes only 8% of overall loan book as against 21% in Q1FY17. Deposits grew 18.1% to INR 7,710 billion, CASA grew 7% and term deposits grew 29% YoY. This led to a YoY/QoQ contraction of 450/ 183bps in CASA ratio, respectively, to 45.1%.

#### Outlook and valuation: Domestic growth momentum to continue; Maintain BUY

Since ascertaining the impact of the COVID-19 pandemic at this point would be difficult, we have cut our loan book growth, revenue and PAT estimates. We have also reduced the valuation multiple, arriving at a revised TP of INR 480. However, considering the relatively higher proportion of retail loans in its overall book, a higher PCR and strong deposit franchise, we believe the bank is best placed to weather this storm. We reiterate our BUY recommendation.

**Raj Jha**

Research Analyst  
raj.jha@edelweissfin.com

**Harsh Vijay Shah**

Research Analyst  
harshv.shah@edelweissfin.com

**Nikhil Shah**

Research Analyst  
nikhil.shah@edelweissfin.com

**CMP INR: 354**

**Rating: BUY**

**TP INR: 480**

**Upside: 36%**

Bloomberg:	ICICI:IN
52-week range (INR):	552/268
Share in issue (crore):	647
M-cap (INR crore):	2,33,366
Average daily volume BSE/NSE ('000):	41,673
Promoter holding (%)	-

Year to March (INR Cr)	FY19	FY20	FY21E	FY22E	FY23E
Net Revenue	41,526	49,715	57,702	60,722	68,931
PPoP	23,437	28,101	34,234	34,699	39,855
PAT	3,363	7,930	13,780	13,916	23,045
EPS	5.2	12.2	21.2	21.4	35.5
ABV	130.7	145.9	153	160.7	188.2
ROA (%)	0.4	0.8	1.2	1.1	1.7
ROE (%)	3.2	7.2	11.7	11	16.5
P/E (x)	39.5	16.8	9.7	9.6	5.8
P/ABV (x)	1.6	1.4	1.3	1.3	1.1

Source: Edelweiss Professional Investor Research

Date: 14<sup>th</sup> July 2020

**Q4FY20 result highlights**

INR crore	Q4FY20	Q4FY19	% change	Q3FY20	% change	FY20	FY19	% change
Interest earned	19,189	17,293	11.0	19,064	0.7	74,798	63,402	18.0
Interest expended	10,262	9,673	6.1	10,519	(2.4)	41,531	36,387	14.1
<b>Net interest income</b>	<b>8,927</b>	<b>7,620</b>	<b>17.1</b>	<b>8,545</b>	<b>4.5</b>	<b>33,267</b>	<b>27,015</b>	<b>23.1</b>
Other income	4,255	3,621	17.5	4,574	(7.0)	16,449	14,512	13.3
<b>Net revenue</b>	<b>13,182</b>	<b>11,241</b>	<b>17.3</b>	<b>13,119</b>	<b>0.5</b>	<b>49,715</b>	<b>41,527</b>	<b>19.7</b>
<b>Operating expenses</b>	<b>5,792</b>	<b>5,008</b>	<b>15.7</b>	<b>5,571</b>	<b>4.0</b>	<b>21,614</b>	<b>18,089</b>	<b>19.5</b>
Employee expense	2,235	1,899	17.7	1,942	15.1	8,271	6,808	21.5
Other expenditure	3,557	3,109	14.4	3,629	(2.0)	13,343	11,281	18.3
<b>Operating profit</b>	<b>7,390</b>	<b>6,234</b>	<b>18.6</b>	<b>7,549</b>	<b>(2.1)</b>	<b>28,101</b>	<b>23,438</b>	<b>19.9</b>
Provisions and contingencies	5,967	5,451	9.5	2,083	186.5	14,053	19,661	(28.5)
<b>PBT</b>	<b>1,423</b>	<b>782</b>	<b>81.9</b>	<b>5,465</b>	<b>(74.0)</b>	<b>14,048</b>	<b>3,777</b>	<b>272.0</b>
Taxes	201	(187)	NA	1,319	(84.7)	6,117	414	1379.0
<b>PAT</b>	<b>1,221</b>	<b>969</b>	<b>26.0</b>	<b>4,146</b>	<b>(70.5)</b>	<b>7,931</b>	<b>3,363</b>	<b>135.8</b>
Adjustment	-	-	-	-	-	-	-	-
<b>Adjusted PAT</b>	<b>1,221</b>	<b>969</b>	<b>26.0</b>	<b>4,146</b>	<b>(70.5)</b>	<b>7,931</b>	<b>3,363</b>	<b>135.8</b>
Number of equity shares (in crore)	647	645	0.4	647	0.1	647	645	0.4
<b>Adjusted EPS (INR)</b>	<b>1.9</b>	<b>1.5</b>	<b>25.5</b>	<b>6.4</b>	<b>(70.6)</b>	<b>12.3</b>	<b>5.2</b>	<b>134.8</b>

**Ratios**

Cost-to-income ratio	43.9%	44.5%	(61)bps	42.5%	148bps	43.5%	43.6%	(8)bps
Yield on IEA (reported)	8.32%	8.45%	(13)bps	8.40%	(8)bps	8.38%	8.03%	35bps
Cost of funds (reported)	4.92%	5.20%	(28)bps	5.06%	(14)bps	5.09%	5.10%	(1)bps
Spread	3.40%	3.25%	15bps	3.34%	6bps	3.29%	2.93%	36bps
NIM (reported)	3.87%	3.72%	15bps	3.77%	10bps	4.01%	3.77%	24bps
RoA	0.5%	0.4%	5bps	1.7%	(120)bps	0.8%	0.4%	42bps

**INR crore**
**Balance Sheet**

Advances	6,45,290	5,86,647	10.0	6,35,654	1.5	6,45,290	5,86,647	10.0
Deposits	7,70,969	6,52,920	18.1	7,16,345	7.6	7,70,969	6,52,920	18.1
Credit-deposit ratio	83.7%	89.8%	(615)bps	88.7%	(504)bps	83.7%	89.8%	(615)bps
CASA	45.1%	49.6%	(450)bps	46.9%	(183)bps	45.1%	49.6%	(450)bps

**INR crore**
**Asset quality**

Amount of gross NPAs	41,409	46,292	(10.5)	43,454	(4.7)	41,409	46,292	(10.5)
Amount of net NPAs	10,114	13,577	(25.5)	10,389	(2.6)	10,114	13,577	(25.5)
% of gross NPAs	6.04	7.4	(134)bps	6.4	(35)bps	6.0	7.4	(134)bps
% of net NPAs	1.54	2.3	(76)bps	1.6	(6)bps	1.5	2.3	(76)bps
Reported PCR (excluding technical write-off)	75.7	70.6	510bps	76.2	(50)bps	75.7	70.6	510bps

## Previous outlook

### Q1FY20 outlook

#### Outlook and valuation: Stellar performance to continue; Reiterate 'Buy'

We believe ICICI bank's overall performance to remain robust on back of: (1) Robust domestic loan growth (2) Softening credit cost (3) Return ratios to improve on back of softening of overall cost. Based on SOTP methodology, we have valued the stock at 2.5x FY21E ABV, valued its overseas subsidiary at INR 10 and valued its other subsidiaries at INR 96 to arrive at target price of INR 548, implying 32% upside. We maintain our 'BUY' recommendation on the stock.

### Q2FY20 outlook

#### Outlook and valuation: Domestic growth momentum to continue; Maintain 'Buy'

We believe ICICI bank's overall performance to remain robust on back of: (1) Robust domestic loan growth (2) Softening credit cost (3) Return ratios to improve on back of softening of overall cost. Based on SOTP methodology, we have valued the stock at 2.6x FY21E ABV, valued its overseas subsidiary at INR 10 and valued its other subsidiaries at INR 96 to arrive at target price of INR 565, implying 18% upside. We maintain our 'BUY' recommendation on the stock.

### Q3FY20 outlook

#### Outlook and valuation: Domestic growth momentum to continue; Maintain 'Buy'

We believe ICICI bank's overall performance to remain robust on back of: (1) Robust domestic loan growth (2) Softening credit cost (3) Return ratios to improve on back of softening of overall cost. We revise our TP to INR 644 per share, rolling forward our valuation to FY22E and valuing the company at 2.5x FY22ABV along with valuation of subsidiary companies, implying 20% upside. We maintain our 'BUY' recommendation on the stock.


#### Q1FY20

#### Q2FY20


#### Q3FY20

## Six quarters at a glance


### Muted corporate & de-growing overseas book dented overall loan growth




### Domestic loan share continues to increase




### Domestic advances share - Retail loan share continues to increase




### Moving towards high quality accounts



### Slippage ratio remains elevated



### One-off COVID-19 provisioning led to higher credit cost



## Six quarters at a glance

INR crore	Q3FY19	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20
<b>Profit &amp; Loss Statement</b>						
Interest income	16,280	17,293	17,980	18,565	19,064	19,189
Interest expense	9,405	9,673	10,243	10,508	10,519	10,262
<b>Net interest income</b>	<b>6,875</b>	<b>7,620</b>	<b>7,737</b>	<b>8,057</b>	<b>8,545</b>	<b>8,927</b>
Other income	3,883	3,621	3,425	4,194	4,574	4,255
<b>Net revenue</b>	<b>10,758</b>	<b>11,241</b>	<b>11,163</b>	<b>12,252</b>	<b>13,119</b>	<b>13,182</b>
<b>Operating expense</b>	<b>4,612</b>	<b>5,008</b>	<b>4,874</b>	<b>5,378</b>	<b>5,571</b>	<b>5,792</b>
- Employee expense	1,734	1,899	1,953	2,141	1,942	2,235
- Other operating expense	2,878	3,109	2,921	3,236	3,629	3,557
<b>Operating profit (PPOP)</b>	<b>6,146</b>	<b>6,234</b>	<b>6,288</b>	<b>6,874</b>	<b>7,549</b>	<b>7,390</b>
Provisions and contingencies	4,244	5,451	3,496	2,507	2,083	5,967
<b>Profit before tax</b>	<b>1,902</b>	<b>782</b>	<b>2,793</b>	<b>4,367</b>	<b>5,465</b>	<b>1,423</b>
Provision for tax	297	(187)	885	3,712	1,319	201
<b>Profit after tax</b>	<b>1,605</b>	<b>969</b>	<b>1,908</b>	<b>655</b>	<b>4,146</b>	<b>1,221</b>
EPS (INR)	2.5	1.5	3.0	1.0	6.4	1.9
<b>Ratios</b>						
Cost-to-income ratio	42.9%	44.5%	43.7%	43.9%	42.5%	43.9%
Yield on interest earning assets	8.1%	8.5%	8.4%	8.4%	8.4%	8.3%
Cost of funds	5.1%	5.2%	5.2%	5.2%	5.1%	4.9%
Spread	2.9%	3.3%	3.2%	3.2%	3.3%	3.4%
NIM	3.4%	3.7%	3.6%	3.6%	3.8%	3.9%
RoA	0.7%	0.4%	0.8%	0.3%	1.7%	0.5%
<b>Balance Sheet</b>						
Advances	5,64,308	5,86,647	5,92,415	6,13,359	6,35,654	6,45,290
Deposits	6,06,755	6,52,920	6,60,732	6,96,273	7,16,345	7,70,969
Credit-deposit ratio (%)	93.0%	89.8%	89.7%	88.1%	88.7%	83.7%
CASA (%)	49.3%	49.6%	45.2%	46.7%	46.9%	45.1%
<b>Asset quality</b>						
Gross NPA	51,591	46,292	45,763	45,639	43,454	41,409
Net NPA	16,252	13,577	11,857	10,916	10,389	10,114
Gross NPA (%)	8.5	7.4	7.2	6.9	6.4	6.0
Net NPA (%)	2.9	2.3	2.0	1.7	1.6	1.5
Provision coverage ratio	65.9%	68.8%	72.2%	74.8%	75.0%	74.5%

## Q4FY20 conference call highlights

### With respect to advances and deposits:

- Focus has moved from growing the corporate book to servicing current corporate customers in terms of forex, derivatives, working capital requirements, etc.
- **Personal loans and credit card:** Around 70% are the bank's customers (mostly liability customers). Of this, 85% customers are salaried and within that 75% are employed with reputable organisations including MNCs and government entities.
- **Business banking:** About 85% of loans have a cover of more than 100%.
- Total exposure (fund+non-fund+investments) to non-banking finance companies (NBFCs)/housing finance companies (HFCs)/builder portfolio stands at INR 273/124/223 billion, respectively.
- Around 30% of mortgage book is loan against property.
- **As of April-end, 30% of bank's total loan book is under moratorium.**

### With respect to asset quality:

- Higher corporate slippages were on account of an overseas healthcare group and a large oil company, which were in the news recently.
- Both accounts were classified as NPA in the quarter under review. Excluding this, slippages would have been lower on a quarter-on-quarter basis.
- Loans that were overdue for more than 90 days as on March 31 but have not been classified as non-performing stood at INR 1,309 crore based on extant Reserve Bank of India (RBI) guidelines. The impact of classification of these loans as non-performing on the gross NPA ratio as of March 31 would have been 18 bps (predominately retail exposure).
- Provisioning for novel coronavirus, or COVID-19, includes INR 607 crore as per RBI guidelines on provisioning of special mention accounts (SMA) under moratorium. The bank has provided for only 5% and the balance (5%) will be undertaken in Q1FY21.

### Other highlights:

- Dividend income from subsidiaries to decrease in FY20-21.
- Management refrains from offering a guidance due to uncertain business environment.
- Focus will be on cost efficiency. However, incremental cost to be incurred for continuous technological upgradation.

### Company description

ICICI Bank is one of India's largest banks with an asset size of INR 1,100 lakh crore. The bank operates 5,324 branches and 15,688 ATMs. It has successfully created a large share of retail loans, constituting ~63% of total loans and advances. The bank enjoys almost market leadership in most of its businesses -- mortgages, auto loans, commercial vehicle loans, life insurance, general insurance and asset management -- either through direct operations or subsidiary companies. Its subsidiaries are ICICI Venture Funds, Pru-ICICI AMC, ICICI Securities, ICICI Prudential and ICICI Lombard.

### Key risks

- Higher moderation in CASA growth from our estimate may impact margin and profitability.
- Delay in economic activity may crimp growth and further deteriorate asset quality, which may impact our projections and target price.
- Prolonged coronavirus-led lockdown can increase provisioning and worsen asset quality for the company.

## Financials

Income statement (INR Cr)	FY18	FY19	FY20	FY21E	FY22E	FY23E
Interest income	54,965	63,401	74,798	81,298	87,734	97,106
Interest expended	31,940	36,386	41,531	44,723	48,184	52,518
Net interest income	23,025	27,014	33,267	36,575	39,549	44,587
Non-interest income	17,419	14,512	16,448	21,126	21,172	24,344
- Fee & forex income	10,534	12,136	13,960	15,611	17,707	20,502
- Misc. income	1,082	1,009	1,194	1,697	1,864	2,241
- Investment profits	5,802	1,366	1,293	3,817	1,600	1,600
Net revenue	40,445	41,526	49,715	57,702	60,722	68,931
Operating expense	15,703	18,089	21,614	23,467	26,022	29,075
- Employee exp	5,913	6,808	8,271	8,602	9,210	10,052
- Other opex	9,789	11,280	13,343	14,865	16,812	19,023
Preprovision profit	24,741	23,437	28,101	34,234	34,699	39,855
Provisions	17,306	19,661	14,053	15,860	16,143	9,128
Loan loss provisions	17,306	19,661	14,053	15,860	16,143	9,128
Investment depreciation	0	0	0	0	0	0
Other provisions	0	0	0	0	0	0
Profit before tax	7,434	3,776	14,048	18,373	18,555	30,727
Provision for tax	657	413	6,117	4,593	4,638	7,681
Profit After Tax	6,777	3,363	7,930	13,780	13,916	23,045
Reported PAT	6,777	3,363	7,930	13,780	13,916	23,045
Basic shares outstanding (mn)	645	644	647	647	647	647
Diluted EPS (INR)	10.4	5.2	12.2	21.2	21.4	35.5
Dividend per share (INR)	1.5	1	0	7	7	7
Dividend payout (%)	16.6	22.2	0	38.2	37.8	22.8

Growth ratios (%)	FY18	FY19	FY20	FY21E	FY22E	FY23E
NII growth	5.9	17.3	23.1	9.9	8.1	12.7
Fees growth	8.3	15.2	15	11.8	13.4	15.7
Opex growth	6.4	15.1	19.4	8.5	10.8	11.7
PPOP growth	5.7	16.5	21.4	13.4	8.8	15.5
PPP growth	-6	-5	19.8	21.8	1.3	14.8
Provisions growth	13.8	13.6	-28	12.8	1.7	-43
Net profit	-31.0	-50.0	135.8	73.7	0.9	65.5

Operating ratios	FY18	FY19	FY20	FY21E	FY22E	FY23E
Yield on advances	8.3	8.7	9.3	8.8	8.6	8.5
Yield on investments	6.8	7.1	7.4	7.2	7	6.8
Yield on assets	7.3	7.5	7.9	7.6	7.4	7.3
Cost of funds	4.4	4.4	4.5	4.3	4.2	4.1
Net interest margins	3	3.2	3.5	3.4	3.3	3.3
Cost of deposits	3.4	3.5	3.8	3.7	3.6	3.6
Cost of borrowings	6.0	5.8	6.0	5.9	5.8	5.7
Spread	2.9	3.1	3.4	3.2	3.2	3.2
Cost-income	38.8	43.5	43.4	40.6	42.8	42.1
Tax rate	8.8	10.9	43.5	25.0	25.0	25.0



**Financials**

<b>Balance sheet</b>	<b>FY18</b>	<b>FY19</b>	<b>FY20</b>	<b>FY21E</b>	<b>FY22E</b>	<b>FY23E</b>
<b>LIABILITIES</b>						
Equity capital	1,291	1,289	1,294	1,294	1,294	1,294
Reserves & surplus	1,01,050	1,04,261	1,12,094	1,20,608	1,29,258	1,47,036
Net worth	1,02,341	1,05,550	1,13,389	1,21,903	1,30,553	1,48,331
Sub bonds/pref cap	73,874	77,194	80,514	80,514	80,514	80,514
Deposits	5,60,975	6,52,919	7,70,968	8,98,178	10,40,989	11,86,727
Borrowings	1,08,984	88,125	82,382	48,605	26,641	32,709
Other liabilities	30,196	37,851	47,995	51,556	45,256	41,969
Total liabilities	8,76,371	9,61,641	10,95,250	12,00,758	13,23,954	14,90,252
<b>Assets</b>						
Loans	5,12,395	5,86,646	6,45,289	7,06,673	7,96,747	9,23,321
Investments	0	0	0	0	0	0
Cash and equivalents	84,169	80,296	1,19,155	1,23,249	1,30,780	1,41,431
Gilts	1,38,078	1,44,503	1,74,937	2,08,292	2,24,202	2,40,229
Others	64,915	63,228	74,594	79,603	85,054	91,003
Fixed assets	5,086	5,113	5,295	4,999	4,677	4,331
Other Assets	71,726	81,852	75,977	77,939	82,490	89,935
Total assets	8,76,371	9,61,641	10,95,250	12,00,758	13,23,954	14,90,252
Book value per share (INR)	158.4	163.7	175.1	188.3	201.6	229.1
Credit growth	10.4	14.5	10.1	9.6	12.7	15.8
Deposit growth	14.4	16.3	18	16.5	15.9	14
EA growth	13.9	9.3	15.9	10.2	10.6	12.8
SLR ratio	20.6	19.5	20.5	22	21	19.7
C-D ratio	95.3	93.5	87.1	81.9	79.6	80.8
Low-cost deposits	51.6	49.6	45.1	45.6	44.2	43.8
Provision coverage	48.4	70.6	75.5	71.1	67.5	65.1
Gross NPA ratio	10.2	7.5	6.1	7	7.2	5.6
Net NPA ratio	5.4	2.3	1.5	2.1	2.4	2
Incremental slippage	6	2	2.3	4.2	3.9	1.9
Net NPA / Equity	27.2	12.8	8.9	12.2	14.9	12.7
Capital adequacy	18.4	16.8	16.1	15.7	15.3	15.1
- Tier 1	15.9	15	14.7	14.3	13.9	13.7


<b>Du pont analysis</b>	<b>FY18</b>	<b>FY19</b>	<b>FY20</b>	<b>FY21E</b>	<b>FY22E</b>	<b>FY23E</b>
Net interest income/assets	3.0	3.2	3.5	3.4	3.3	3.3
Fees/Assets	1.5	1.5	1.6	1.6	1.6	1.7
Investment profits/Assets	0.7	0.1	0.1	0.3	0.1	0.1
Net revenues/assets	5.3	4.9	5.2	5.4	5.1	5.2
Operating expense/assets	-2.0	-2.0	-2.0	-2.0	-2.0	-2.0
Provisions/assets	-2.0	-2.0	-1.0	-1.0	-1.0	-1.0
Taxes/assets	0.0	0.0	-1.0	0.0	0.0	0.0
Total costs/assets	-4.0	-4.0	-4.0	-4.0	-4.0	-3.0
ROA	0.9	0.4	0.8	1.2	1.1	1.7
Equity/assets	13.2	12.4	11.5	11.0	10.7	10.5
ROAE (%)	6.7	3.2	7.2	11.7	11.0	16.5

<b>Valuation parameters</b>	<b>FY18</b>	<b>FY19</b>	<b>FY20</b>	<b>FY21E</b>	<b>FY22E</b>	<b>FY23E</b>
Diluted EPS (INR)	10.4	5.2	12.2	21.2	21.4	35.5
Y-o-Y growth (%)	-37.0	-50.0	134.8	73.7	0.9	65.5
Book value per share (INR)	158.4	163.7	175.1	188.3	201.6	229.1
Adjusted book value per share (INR)	111.0	130.7	145.9	153.0	160.7	188.2
Diluted PE (x)	19.8	39.5	16.8	9.7	9.6	5.8
Price/BV (x)	1.3	1.3	1.2	1.1	1.0	0.9
Price/ Adj. BV (x)	1.9	1.6	1.4	1.3	1.3	1.1

Edelweiss Broking Limited, 1st Floor, Tower 3, Wing B, Kohinoor City Mall, Kohinoor City, Kirod Road, Kurla(W)  
Board: (91-22) 4272 2200

Vinay Khattar  
Head Research  
vinay.khattar@edelweissfin.com

Rating	Expected to
BUY	appreciate more than 15% over a 12-month period
HOLD	appreciate between 5% and 15% over a 12-month period
REDUCE	return below 5% over a 12-month period



## Disclaimer

Edelweiss Broking Limited ("EBL" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of EBL and its Associates (list available on [www.edelweissfin.com](http://www.edelweissfin.com)) are organized around five broad business groups – Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance.

Broking services offered by Edelweiss Broking Limited under SEBI Registration No.: INZ000005231; Name of the Compliance Officer: Mr. Brijmohan Bohra, Email ID: [complianceofficer.ebl@edelweissfin.com](mailto:complianceofficer.ebl@edelweissfin.com) Corporate Office: Edelweiss House, Off CST Road, Kalina, Mumbai - 400098; Tel. 18001023335/022-42722200/022-40094279

This Report has been prepared by Edelweiss Broking Limited in the capacity of a Research Analyst having SEBI Registration No. INH000000172 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject EBL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. EBL reserves the right to make modifications and alterations to this statement as may be required from time to time. EBL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. EBL is committed to providing independent and transparent recommendation to its clients. Neither EBL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance. The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The information provided in these reports remains, unless otherwise stated, the copyright of EBL. All layout, design, original artwork, concepts and other Intellectual Properties, remains the property and copyright of EBL and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the copyright holders.

EBL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the EBL to present the data. In no event shall EBL be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the EBL through this report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

EBL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. EBL may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with EBL.

EBL or its associates may have received compensation from the subject company in the past 12 months. EBL or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. EBL or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EBL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or EBL's associates may have financial interest in the subject company. EBL, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No  
EBL has financial interest in the subject companies: No

EBL's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

EBL has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No  
Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years.  
A graph of daily closing prices of the securities is also available at [www.nseindia.com](http://www.nseindia.com)

### Analyst Certification:

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

## Disclaimer

### Additional Disclaimer for U.S. Persons

Edelweiss is not a registered broker – dealer under the U.S. Securities Exchange Act of 1934, as amended (the “1934 act”) and under applicable state laws in the United States. In addition Edelweiss is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the “Advisers Act” and together with the 1934 Act, the “Acts”), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by Edelweiss, including the products and services described herein are not available to or intended for U.S. persons.

This report does not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services and/or shall not be considered as an advertisement tool. “U.S. Persons” are generally defined as a natural person, residing in the United States or any entity organized or incorporated under the laws of the United States. US Citizens living abroad may also be deemed “US Persons” under certain rules.

Transactions in securities discussed in this research report should be effected through Edelweiss Financial Services Inc.

### Additional Disclaimer for U.K. Persons

The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (“FSMA”).

In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the “Order”); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as “relevant persons”).

This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this research report or any of its contents. This research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person.

### Additional Disclaimer for Canadian Persons

Edelweiss is not a registered adviser or dealer under applicable Canadian securities laws nor has it obtained an exemption from the adviser and/or dealer registration requirements under such law. Accordingly, any brokerage and investment services provided by Edelweiss, including the products and services described herein, are not available to or intended for Canadian persons.

This research report and its respective contents do not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services.

### Disclosures under the provisions of SEBI (Research Analysts) Regulations 2014 (Regulations)

Edelweiss Broking Limited (“EBL” or “Research Entity”) is regulated by the Securities and Exchange Board of India (“SEBI”) and is licensed to carry on the business of broking, depository services and related activities. The business of EBL and its associates are organized around five broad business groups – Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance. There were no instances of non-compliance by EBL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. This research report has been prepared and distributed by Edelweiss Broking Limited (“Edelweiss”) in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No.INH000000172.